General Information of Drug (ID: DMMLDG8)

Drug Name
Anatumomab mafenatox Drug Info
Synonyms ABR-214936; Fab5T4V13-SEAm9; PNU-214936; TTS-CD2; CD-2, Active Biotech
Indication
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Terminated [1]
Cross-matching ID
TTD Drug ID
DMMLDG8

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Preclinical Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
TroVax DMHDNK0 Prostate cancer 2C82.0 Phase 3 [2]
Naptumomab estafenatox DM901ZW Solid tumour/cancer 2A00-2F9Z Phase 2/3 [3]
CV-9201 DMCPZYT Non-small-cell lung cancer 2C25.Y Phase 1/2 [4]
GEN1044 DMQ9317 Solid tumour/cancer 2A00-2F9Z Phase 1 [5]
PF-06263507 DM5KBDY Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
IM1240 DMTV0DK Aggressive cancer 2A00-2F9Z Preclinical [7]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Oncotrophoblast glycoprotein 5T4 (TPBG) TT70MLA TPBG_HUMAN Not Available [1]

References

1 A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer. 2007 Feb 26;96(4):567-74.
2 Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010 Nov 15;16(22):5539-47.
3 Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370.
4 National Cancer Institute Drug Dictionary (drug id 648549).
5 Clinical pipeline report, company report or official report of AbbVie.
6 National Cancer Institute Drug Dictionary (drug id 751006).
7 Clinical pipeline report, company report or official report of Purple